The molecular mechanisms associated with CD19-CAR T cell therapy resistance are linked to CAR T cell fitness, tumor-intrinsic determinants, host-related factors, and tumor microenvironment (TME) characteristics [11]. Here, CD19 is linked to neoplasm.